Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 245

Sort by

Sort Order Select

Journal Articles

Altered Iron Metabolism Is a New Targetable Hallmark for Multiple Myeloma

Can Li, MD, Xuelian Tan, Qierra Brockman, BA, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Marta Chesi, PhD, P. Leif Bergsagel, MD, Fangping Chen, MD PhD, Ivana Frech, DSc, PhD MBA, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 3059.

https://doi.org/10.1182/blood-2019-123473

Published: 2019

Journal Articles

Higher Stability of Mutant IDH1/2 mRNA As Compared to Wild-Type mRNA in Patients with Acute Myeloid Leukemia

Maher Albitar, MD, Marina Y Konopleva, MD PhD, Ivan De Dios, BS, Jeffrey Justin Estella, BS, MS, Spiraggelos Antzoulatos, Steven M. Kornblau, MD, Antonio Cavazos, Sanam Loghavi, MD, Koichi Takahashi, MD, Hagop M. Kantarjian, MD, Courtney D. DiNardo, MDMSc

Blood (2019) 134 (Supplement_1): 2730.

https://doi.org/10.1182/blood-2019-127383

Published: 2019

Journal Articles

Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Blood (2019) 134 (Supplement_1): 581.

https://doi.org/10.1182/blood-2019-127717

Published: 2019

Journal Articles

Quantitative Immunoprecipitation Free Light Chain Mass Spectrometry (QIP-FLC-MS) Simplifies Monoclonal Protein Assessment and Provides Added Clinical Value in Systemic AL Amyloidosis

Faye Amelia Sharpley, BA MA MSc MBBChir FRCPath, Hannah Victoria Giles, FRCPath, MRCP, Richa Manwani, MBBS, FRCPath, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Helen J Lachmann, MA MB BChir MDFRCP, Julian D Gillmore, MBBS, MD PhD FRCP, Carol J Whelan, Philip N Hawkins, Ashutosh D Wechalekar, MB BS, MD FRCP, FRCPath, DM

Blood (2019) 134 (Supplement_1): 4375.

https://doi.org/10.1182/blood-2019-128175

Published: 2019

Journal Articles

MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy

Marion Eveillard, Malin Hultcrantz, MD PhD, Alexander M. Lesokhin, MD, Sham Mailankody, MBBS, Eric L Smith, MD PhD, Hani Hassoun, MD, Urvi A Shah, MD, Sydney X Lu, MD PhD, Neha Korde, MD, Ola Landgren, MD PhD, Katie Thoren, PhD

Blood (2019) 134 (Supplement_1): 4377.

https://doi.org/10.1182/blood-2019-128938

Published: 2019

Journal Articles

Targeted Mass Spectrometry-Based Serum M-Protein Monitoring for Early Relapse Detection

Zac McDonald, PhD, Mariya Liyasova, PhD, Paul Taylor, Xin Xu, Kathleen Gorospe, Chenyu Yao, Qixin Liu, Liqiang Yang, PhD, Bin Ma, PhD, Jesus Piza, MD, Donna E Reece, MD, Suzanne Trudel, MD

Blood (2019) 134 (Supplement_1): 4347.

https://doi.org/10.1182/blood-2019-130251

Published: 2019

Journal Articles

The Use of Next Generation Gene Sequencing to Measure Minimal Residual Disease in Patients with AL Amyloidosis and Low Plasma Cell Burden: A Feasibility Study

Shayna Sarosiek, Vaishali Sanchorawala, MD, Mariateresa Fulcinti, Allison P. Jacob, Nikhil C. Munshi, MD, Cindy Varga, MD BSc

Blood (2019) 134 (Supplement_1): 4353.

https://doi.org/10.1182/blood-2019-131863

Published: 2019

Journal Articles

Amyloidosis and Plasma Cell Dyscrasias: A Single Institution Experience

Poornima Ramadas, MBBS, Ajay Tambe, MBBS, Mijung Lee, MD

Blood (2019) 134 (Supplement_1): 5463.

https://doi.org/10.1182/blood-2019-131577

Published: 2019

Journal Articles

Treatment of Non-Amyloid Monoclonal Gammopathies of Renal Significance (MGRS) with Clone Directed Therapies-Single Center Experience

Divaya Bhutani, MD, Vikram Premkumar, MD, Shayan Shirazayan, MD, Andrew Bomback, MD, Jai Radhakrishnan, MD, Suzanne Lentzsch, MD PhD

Blood (2019) 134 (Supplement_1): 5565.

https://doi.org/10.1182/blood-2019-128455

Published: 2019

Journal Articles

Infectious Complications Following Venetoclax-Proteasome Inhibitor Based Regimens in Relapsed Myeloma: A Single Center Retrospective Analysis

Christopher Tor Sauter, MD, Luca L Bernabei, BA, Adam Waxman, MD, Adam D. Cohen, MD, Alfred L. Garfall, MD, Dan T. Vogl, MD, Sara Whittington,, RN, MPH, Colleen Harker Erb, CRNP, Patricia Mangan, CRNP, Mary Sanchez, CRNP, Edward A. Stadtmauer, MD FACP

Blood (2019) 134 (Supplement_1): 5598.

https://doi.org/10.1182/blood-2019-132087

Published: 2019

Journal Articles

Monoclonal Gammopathy with Secondary Atypical Hemolytic-Uremic Syndrome

Trisha Kissoon, MD MBA, Sudha Mannemuddhu, MD, Mansi Dalal, MD, Lawrence Shoemaker, MD

Blood (2019) 134 (Supplement_1): 5465.

https://doi.org/10.1182/blood-2019-131826

Published: 2019

Journal Articles

Incidental Pulmonary Embolism. Analysis of Mayo Clinic Venous Thromboembolism Database

Ewa Wysokinska, MD, Damon E. Houghton, MDMS, Danielle Vlazny, PA-C, Aneel A. Ashrani, MD MS, David A Froehling, MD, David O. Hodge, MS, Lisa Peterson, RN, Robert D. McBane, MD, Waldemar E. Wysokinski, MD PhD, Ana I Casanegra, MD

Blood (2019) 134 (Supplement_1): 1147.

https://doi.org/10.1182/blood-2019-131547

Published: 2019

Journal Articles

Hypogammaglobulinemia and Its Implications in Patients Treated with Daratumumab: A Single Institution Experience

Yonette Paul, MD MBBS, Luis E. Aguirre, MD, Fahmin Basher, MD PhD, Feng Miao, MS, Tulay Koru-Sengul, PhD, James E. Hoffman, MD

Blood (2019) 134 (Supplement_1): 3131.

https://doi.org/10.1182/blood-2019-127247

Published: 2019

Journal Articles

Single Arm, Prospective, Open-Label Phase II Trial to Evaluate the Efficacy of Isatuximab in Patients with Monoclonal Gammopathy of Renal Significance

Vikram Premkumar, MD, Suzanne Lentzsch, MD PhD, Divaya Bhutani, MD

Blood (2019) 134 (Supplement_1): 3161.

https://doi.org/10.1182/blood-2019-123496

Published: 2019

Journal Articles

Development of an Easily Accessible Patient-Derived Xenograft (PDX) Mouse Model in Multiple Myeloma

Can Li, MD, Yogesh Jethava, MBBS, MDFRCPath, MRCP, Ivana Frech, DSc, PhD MBA, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 5538.

https://doi.org/10.1182/blood-2019-121933

Published: 2019

Journal Articles

Higher Stability of Mutant mRNA As Compared to Wild-Type mRNA in Diffuse Large B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 1499.

https://doi.org/10.1182/blood-2019-128516

Published: 2019

Journal Articles

Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Blood (2019) 134 (Supplement_1): 1852.

https://doi.org/10.1182/blood-2019-128655

Published: 2019

Journal Articles

Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone +/- Elotuzumab

Ann Forslund, PhD, Hao Tang, Chunzhe Duan, Mihaela Popa-McKiver, PhD, James R. Berenson, MD, Michael Robbins, PhD

Blood (2019) 134 (Supplement_1): 1853.

https://doi.org/10.1182/blood-2019-128760

Published: 2019

Journal Articles

The Utilization of Screening Tests for Plasma Cell Dyscrasias By Internal Medicine Physicians at a Teaching Hospital

Omar Abughanimeh, MD, Ahmad Al-Shyoukh, Anahat Kaur, MD, Diala Alawneh, Soheila Hamidpour, Anuj Shrestha, MD, Sheshadri Madhusudhana, MD

Blood (2019) 134 (Supplement_1): 4732.

https://doi.org/10.1182/blood-2019-123077

Published: 2019

Journal Articles

Approximating International Myeloma Working Group Uniform Response Criteria to Derive Response for Multiple Myeloma (MM) Patients Using Data from Electronic Health Records (EHR)

Rebekah B. Foster, BA, Max Tromanhauser, BSE, Christopher Gayer, PhD, Patrick K. Gonzales, MS, Kathleen Maignan, NP, Adomah S. Opong, ANP, Aracelis Z. Torres, MPH, PhD, Kenneth R. Carson, MD PhD

Blood (2019) 134 (Supplement_1): 4727.

https://doi.org/10.1182/blood-2019-127181

Published: 2019

NARROW

Altered Iron Metabolism Is a New Targetable Hallmark for Multiple Myeloma

Higher Stability of Mutant IDH1/2 mRNA As Compared to Wild-Type mRNA in Patients with Acute Myeloid Leukemia

Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Quantitative Immunoprecipitation Free Light Chain Mass Spectrometry (QIP-FLC-MS) Simplifies Monoclonal Protein Assessment and Provides Added Clinical Value in Systemic AL Amyloidosis

MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy

Targeted Mass Spectrometry-Based Serum M-Protein Monitoring for Early Relapse Detection

The Use of Next Generation Gene Sequencing to Measure Minimal Residual Disease in Patients with AL Amyloidosis and Low Plasma Cell Burden: A Feasibility Study

Amyloidosis and Plasma Cell Dyscrasias: A Single Institution Experience

Treatment of Non-Amyloid Monoclonal Gammopathies of Renal Significance (MGRS) with Clone Directed Therapies-Single Center Experience

Infectious Complications Following Venetoclax-Proteasome Inhibitor Based Regimens in Relapsed Myeloma: A Single Center Retrospective Analysis

Monoclonal Gammopathy with Secondary Atypical Hemolytic-Uremic Syndrome

Incidental Pulmonary Embolism. Analysis of Mayo Clinic Venous Thromboembolism Database

Hypogammaglobulinemia and Its Implications in Patients Treated with Daratumumab: A Single Institution Experience

Single Arm, Prospective, Open-Label Phase II Trial to Evaluate the Efficacy of Isatuximab in Patients with Monoclonal Gammopathy of Renal Significance

Development of an Easily Accessible Patient-Derived Xenograft (PDX) Mouse Model in Multiple Myeloma

Higher Stability of Mutant mRNA As Compared to Wild-Type mRNA in Diffuse Large B-Cell Lymphoma

Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone +/- Elotuzumab

The Utilization of Screening Tests for Plasma Cell Dyscrasias By Internal Medicine Physicians at a Teaching Hospital

Approximating International Myeloma Working Group Uniform Response Criteria to Derive Response for Multiple Myeloma (MM) Patients Using Data from Electronic Health Records (EHR)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only